Drug Library

Navigate FDA-approved prescribing information for 93 oncology therapies. Each drug page provides structured access to indications, dosing, warnings, and clinical trial data.

93
Drug Pages
50+
Tumor Types
246
Cross-Links
Showing all 93 drugs
Abecma
idecabtagene vicleucel
CAR T-Cell Therapy (BCMA-targeted)
Adcetris
brentuximab vedotin
Antibody-Drug Conjugate (CD30-targeted)
Afinitor
everolimus
mTOR Inhibitor
Alimta
pemetrexed
Antifolate Antimetabolite
Arranon
nelarabine
Purine Nucleoside Analog (Deoxyguanosine)
Avastin
bevacizumab
VEGF Inhibitor (Anti-Angiogenic)
Bavencio
avelumab
PD-L1 Inhibitor
Besponsa
inotuzumab ozogamicin
Blincyto
blinatumomab
Bosulif
bosutinib
BCR-ABL/SRC Kinase Inhibitor
Breyanzi
lisocabtagene maraleucel
CAR T-Cell Therapy (CD19-targeted)
Brukinsa
zanubrutinib
Cabometyx
cabozantinib
Calquence
acalabrutinib
BTK Inhibitor
Caprelsa
vandetanib
Multi-Kinase Inhibitor (EGFR/VEGFR/RET)
Carvykti
ciltacabtagene autoleucel
CAR T-Cell Therapy (BCMA-targeted)
CeeNU / Gleostine
lomustine (CCNU)
Nitrosourea Alkylating Agent
Clolar
clofarabine
Purine Nucleoside Antimetabolite
Columvi
glofitamab-gxbm
Bispecific Antibody (CD20 × CD3)
Cyramza
ramucirumab
VEGFR-2 Antagonist
Darzalex
daratumumab
Doxil
doxorubicin HCl liposome injection
Anthracycline (Liposomal)
Elrexfio
elranatamab-bcmm
Bispecific Antibody (BCMA × CD3)
Empliciti
elotuzumab
Anti-SLAMF7 Monoclonal Antibody
Enhertu
fam-trastuzumab deruxtecan-nxki
Epkinly
epcoritamab-bysp
Bispecific Antibody (CD20 × CD3)
Erbitux
cetuximab
EGFR Inhibitor (Monoclonal Antibody)
Erleada
apalutamide
Androgen Receptor Inhibitor
Fotivda
tivozanib
VEGFR Inhibitor (TKI)
Gavreto
pralsetinib
RET Kinase Inhibitor
Gazyvaro
obinutuzumab
Gleevec
imatinib
BCR-ABL Tyrosine Kinase Inhibitor
Gliadel Wafer
carmustine implant
Nitrosourea Alkylating Agent (Implant)
Halaven
eribulin mesylate
Microtubule Dynamics Inhibitor
Herceptin
trastuzumab
Iclusig
ponatinib
BCR-ABL Tyrosine Kinase Inhibitor
Idhifa
enasidenib
IDH2 Inhibitor
Imbruvica
ibrutinib
Imdelltra
tarlatamab-dlle
Bispecific T-cell Engager (BiTE) — DLL3/CD3
Imfinzi
durvalumab
Imlygic
talimogene laherparepvec
Oncolytic Viral Therapy (HSV-1 Based)
Inlyta
axitinib
VEGFR Inhibitor (TKI)
Jaypirca
pirtobrutinib
Non-Covalent (Reversible) BTK Inhibitor
Jemperli
dostarlimab-gxly
PD-1 Inhibitor
Jevtana
cabazitaxel
Taxane (Semi-synthetic)
Keytruda
pembrolizumab
PD-1 Inhibitor
Kimmtrak
tebentafusp-tebn
Bispecific gp100 Peptide-HLA-directed CD3 T-cell Engager
Kymriah
tisagenlecleucel
CAR T-Cell Therapy (CD19-targeted)
Kyprolis
carfilzomib
Proteasome Inhibitor
Lenvima
lenvatinib
Libtayo
cemiplimab-rwlc
PD-1 Inhibitor
Loqtorzi
toripalimab-tpzi
PD-1 Inhibitor
Lunsumio
mosunetuzumab-axgb
Bispecific Antibody (CD20/CD3)
Lurbinectedin
lurbinectedin
Lutathera
lutetium Lu 177 dotatate
Peptide Receptor Radionuclide Therapy (PRRT)
Lynparza
olaparib
PARP Inhibitor
Lytgobi
futibatinib
FGFR Inhibitor (Pan-FGFR, Irreversible)
Mekinist
trametinib
MEK Inhibitor
Minjuvi
tafasitamab-cxix
Mylotarg
gemtuzumab ozogamicin
Antibody-Drug Conjugate (CD33-targeted)
Nexavar
sorafenib
Ninlaro
ixazomib
Nubeqa
darolutamide
Androgen Receptor Inhibitor
Onureg
azacitidine tablets
Nucleoside Metabolic Inhibitor (Oral Hypomethylating Agent)
Opdivo
nivolumab
PD-1 Inhibitor
Opdualag
nivolumab + relatlimab-rmbw
PD-1/LAG-3 Inhibitor (Fixed-Dose Combination)
Optune
tumor treating fields (TTFields)
Orgovyx
relugolix
GnRH Receptor Antagonist (Oral)
Pemazyre
pemigatinib
FGFR Inhibitor
Pluvicto
lutetium Lu 177 vipivotide tetraxetan
Radioligand Therapy (PSMA-targeted)
Polivy
polatuzumab vedotin-piiq
Antibody-Drug Conjugate (CD79b-targeted)
Pomalyst
pomalidomide
Immunomodulatory Agent (IMiD)
Poteligeo
mogamulizumab-kpkc
Anti-CCR4 Monoclonal Antibody
Provenge
sipuleucel-T
Autologous Cellular Immunotherapy
Retevmo
selpercatinib
RET Kinase Inhibitor
Revlimid
lenalidomide
Revuforj
revumenib
Menin Inhibitor
Rezlidhia
olutasidenib
IDH1 Inhibitor
Rituximab (Rituxan/MabThera)
Rozlytrek
entrectinib
NTRK/ROS1 Inhibitor
Rubraca
rucaparib
PARP Inhibitor
Rydapt
midostaurin
Multi-Kinase Inhibitor (FLT3/KIT)
Rylaze
asparaginase erwinia chrysanthemi (recombinant)
Enzyme Therapy (L-Asparaginase)
Sarclisa
isatuximab-irfc
Anti-CD38 Monoclonal Antibody
Scemblix
asciminib
STAMP Inhibitor (BCR-ABL1 Allosteric)
Sprycel
dasatinib
BCR-ABL/SRC Kinase Inhibitor
Stivarga
regorafenib
Sutent
sunitinib
Multi-Kinase Inhibitor
Tafinlar
dabrafenib
BRAF Inhibitor
Talvey
talquetamab-tgvs
Bispecific Antibody (GPRC5D × CD3)
Talzenna
talazoparib
PARP Inhibitor
Targretin
bexarotene
Retinoid X Receptor (RXR) Agonist
Tasigna
nilotinib
BCR-ABL Tyrosine Kinase Inhibitor
Taxol
paclitaxel
Taxane (Microtubule-Stabilizing Agent)
Tazverik
tazemetostat
EZH2 Inhibitor
Tecartus
brexucabtagene autoleucel
CAR T-Cell Therapy (CD19-targeted)
Tecentriq
atezolizumab
Tecvayli
teclistamab-cqyv
Bispecific Antibody (BCMA × CD3)
Temodar
temozolomide
Tibsovo
ivosidenib
IDH1 Inhibitor
Tivdak
tisotumab vedotin-tftv
Antibody-Drug Conjugate (Tissue Factor-targeted)
Trodelvy
sacituzumab govitecan-hziy
Antibody-Drug Conjugate (Trop-2-targeted)
Velcade
bortezomib
Venclexta
venetoclax
BCL-2 Inhibitor
Voranigo
vorasidenib
Dual IDH1/IDH2 Inhibitor
Votrient
pazopanib
Multi-Kinase Inhibitor (VEGFR/PDGFR/KIT)
Vyxeos
daunorubicin and cytarabine liposome
Liposomal Anthracycline + Antimetabolite
Welireg
belzutifan
HIF-2α Inhibitor
Xalkori
crizotinib
ALK/ROS1/MET Inhibitor
Xermelo
telotristat ethyl
Tryptophan Hydroxylase Inhibitor
Xofigo
radium Ra 223 dichloride
Alpha-Emitting Radiopharmaceutical
Xospata
gilteritinib
FLT3 Inhibitor
Xpovio
selinexor
Nuclear Export Inhibitor (XPO1/CRM1)
Xtandi
enzalutamide
Androgen Receptor Inhibitor
Yervoy
ipilimumab
CTLA-4 Inhibitor
Yescarta
axicabtagene ciloleucel
CAR T-Cell Therapy (CD19-targeted)
Zynlonta
loncastuximab tesirine-lpyl
Antibody-Drug Conjugate (CD19-targeted)
Zytiga
abiraterone acetate
CYP17 Inhibitor